PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine
Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), David Avigan(Beth Israel Deaconess Medical Center), Michael Schickler(CureTech (Israel)), Brett Glotzbecker(Dana-Farber Cancer Institute), Donald Küfe(Dana-Farber Cancer Institute), Whitney Keefe(Dana-Farber Cancer Institute), Baldev Vasir(Beth Israel Deaconess Medical Center), Dimitrios Tzachanis(Dana-Farber Cancer Institute), Kerry Wellenstein(Beth Israel Deaconess Medical Center), Heidi Mills(Beth Israel Deaconess Medical Center), Robin Joyce(Beth Israel Deaconess Medical Center), James D. Levine(Beth Israel Deaconess Medical Center), Rinat Rotem‐Yehudar(Tel Aviv University)
Cited by 285
Related Papers
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
|Journal of Clinical Oncology|2002|1.2k
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
|New England Journal of Medicine|2011|1.1k